Understand the source comparison
Best Peptides for H Pylori: Research Comparison
This table compares antimicrobial peptides with demonstrated activity against H pylori based on mechanism, delivery method, and research-stage evidence. BPC-157 Membrane disruption + gastric cytoprotection Oral (encapsulated) or subcutaneous 10–50 Preclinical
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- This table compares antimicrobial peptides with demonstrated activity against H pylori based on mechanism, delivery method, and research-stage evidence.
- BPC-157
- Membrane disruption + gastric cytoprotection
- Oral (encapsulated) or subcutaneous
- 10–50
- Preclinical (animal models)
- Strongest evidence for direct bactericidal activity combined with mucosal healing. Dual benefit addresses pathogen and tissue damage simultaneously
- KPV (tripeptide)
- Membrane disruption + NF-kappaB inhibition
- Oral (enteric-coated) or subcutaneous
- 25–100
- Preclinical (organoid models)
- Unique anti-inflammatory mechanism reduces cytokine-driven epithelial damage. Particularly valuable in patients with chronic gastritis or ulcer disease
- Thymosin alpha-1
- Immune modulation (Th1 polarisation)
- Subcutaneous only
- N/A (not directly antimicrobial)
- Phase II/III (viral infections)
- Doesn't kill H pylori directly but restores immune clearance capacity. Best used as adjuvant to antimicrobial therapy rather than monotherapy
- LL-37 (cathelicidin)
- Membrane disruption + LPS neutralisation
- Topical (research use)
- 5–20
- Preclinical
- Potent antimicrobial activity but limited oral bioavailability. Current formulations require direct mucosal application
- Lactoferrin (antimicrobial protein)
- Iron sequestration + biofilm disruption
- Oral (high-dose supplementation)
- 50–200
- Phase II (combination trials)
- Widely studied as adjuvant to triple therapy. Reduces biofilm formation but weak standalone activity